Page 21 - Lupin

New launches, cost-control efforts, margin improvement crucial for Lupin

Resolution of compliance issues at Goa, Indore plants are other triggers

Lupin steps up production of key drugs in potential use for Covid-19

Expects US approval for Albuterol soon

Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales

On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.

Lupin Q4 net profit up 35% to Rs 390 cr on robust sales, lower tax expenses

In the current times, Lupin has been able to ensure business continuity while safeguarding the health and safety of its employees

Market Ahead, May 28: Top factors that could guide markets today

A total of 24 companies, including TVS Motor, Lupin, and Federal Bank, are scheduled to announce their March quarter results today

Four in a lift, facing the wall: Office etiquette in Covid-19 times

The second of a 3-part series discusses precautions taken by firms to keep employees safe

Bull Spread strategy on Lupin by Nandish Shah of HDFC Securities

Primary trend of the stock is positive where stock price is trading above its 100 and 200-day SMA

Rakesh Jhunjhunwala cuts stake in Titan, Lupin, Escorts in March quarter

Currently, Rakesh Jhunjhunwala and his family's net worth in listed companies stands at Rs 8,517 crore, compared to Rs 8,388 crore as on March 31, 2020.

Top stock picks by CapitalVia Global Research: Buy Sun Pharma, Lupin

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Lupin gets inspection closure report from USFDA for Pithampur plant

Lupin Managing Director Nilesh Gupta, said the company has received the EIR for the plant with Voluntary Action Indicated (VAI) status

Clearance from US drug regulator key for Lupin to sustain stock gains

The recent gains came on Monday after the company received the USFDA approval for its Nagpur facility

Lupin gets EIR from USFDA for its manufacturing plant in Nagpur

The company's shares surged 4.14% to Rs 820.40 after they received the inspection report (EIR) from the US drug regulator

Lupin gets EIR from USFDA for Florida-based inhalation research centre

The Center at Coral Springs, Florida, focuses on research and development of respiratory products for the treatment of asthma, chronic obstructive pulmonary diseases and other respiratory ailments.

Nifty outlook and top stock recommendations by CapitalVia: Buy Lupin, ITC

Stock of Lupin is showing sign of oversold on RSI indicator. Breakout from the level of 638 would lead stock to witness more upward movement.

Stock calls by Sameet Chavan of Angel Broking: Buy Sun TV Network, Lupin

Once the banking stocks start chipping in, the Nifty is likely to reclaim 12,220 - 12,300 in coming weeks

Lupin Q3 net loss widens to Rs 835 crore, sales drop to Rs 3,716 crore

Consolidated sales of the company stood at Rs 3,716 crore for the quarter under consideration

Market Ahead, February 3: Top factors that could guide markets this week

On the corporate earnings front, Bharti Airtel, Lupin, Sun Pharma, and Mahindra & Mahindra are among the major companies scheduled to declare their October-December results this week

USFDA classifies inspection of Lupin unit as 'Official Action Indicated'

Official Action Indicated means 'objectionable conditions were found and regulatory administrative sanctions by FDA are indicated' during inspections

Lupin dips 2% as USFDA classifies Tarapur unit as Official Action Indicated

The company, however, said it does not believe that this inspection classification will have an impact on disruption of supplies or the existing revenues from operations of this facility.

Nifty view & two stocks that Sameet Chavan of Angel Broking is bullish on

Stock calls and Outlook on Nifty by Mr. Sameet Chavan, Chief Analyst- Technical & Derivatives, Angel Broking Ltd.